PTD-mFOXP3, which was administered via local subcutaneous injection, significantly reduced DTH-induced inflammation, including ear swelling (ear swelling, P<0.001; pinnae weight, P<0.05 or P<0.01 with 0.25 and 1.25 mg/kg PTD-mFOXP3, respectively), infiltration of T cells, and expression of interferon-γ at local inflammatory sites (mRNA level P<0.05) compared with the DTH group.
Pretreatment of cell-permeable Hsp70: (i) suppressed ear swelling; (ii) down-regulated phosphorylated p38, but up-regulated phosphorylated extracellular signal-regulated kinase; (iii) increased population of CD4(+) CD25(+) Foxp3(+) T cells; (iv) decreased secretion of tumor necrosis factor-α (TNF-α), IL-12, interferon-γ and IL-2 and (v) but up-regulated IL-4 and transforming growth factor beta (TGF-β) in the lymph nodes.